amgen news - Search News

Amgen, Obesity

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen's weight-loss drug fails to impress in study; shares plunge

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.

Wide Trading Range For Amgen Stock Makes This Option Shine

Amgen posted earnings that were better than expected last month. Because Amgen stock has heavy institutional ownership, ...

11hon MSN

Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...

Seeking Alpha2d

Amgen: Checks All The Wrong Boxes

In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...

2d

Amgen price target lowered to $330 from $360 at RBC Capital

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

3d

Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results